Evidence map›Paper›PMID 23681255›Full record

ReviewIntegrative biology : quantitative biosciences from nano to macro2013

Building risk-on-a-chip models to improve breast cancer risk assessment and prevention.

Pierre-Alexandre Vidi, James F Leary, Sophie A Lelièvre

Abstract readReview
In one paragraph

Review in Integrative biology : quantitative biosciences from nano to macro, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Tumor-on-chip platforms for breast cancer continuum concept modeling.Frontiers in bioengineering and biotechnology · 2024
    Review
  3. Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro.Integrative biology : quantitative biosciences from nano to macro · 2020
    Review
  4. Article
  5. Architecture in 3D cell culture: An essential feature for in vitro toxicology.Toxicology in vitro : an international journal published in association with BIBRA · 2017
    Review
  6. Article
  7. Article
  8. Taking a chance on epigenetics.Frontiers in genetics · 2014
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pierre-Alexandre VidiDepartment of Basic Medical Sciences and Center for Cancer Research, Purdue University, 625 Harrison Street, Lynn Hall, West Lafayette, IN 47907-2026, USA. lelievre@purdue.edu.
James F Leary
Sophie A Lelièvre

Funding

NuMA function in nonmalignant and malignant breast cellsR01CA112017 · NCI · PURDUE UNIVERSITY · PI LELIEVRE, SOPHIE A. · 2007 to 2012
$872k
Interplay Between Tissue Architecture and Nuclear Organization in the DNA DamageK99CA163957 · NCI · PURDUE UNIVERSITY · PI VIDI, PIERRE-ALEXANDRE · 2012 to 2013
$180k
NCI NIH HHS 1K99CA163957NCI NIH HHS K99 CA163957NCI NIH HHS R01 CA112017NCI NIH HHS R01CA112017
6 · The paper itself

Abstract

Preventive actions for chronic diseases hold the promise of improving lives and reducing healthcare costs. For several diseases, including breast cancer, multiple risk and protective factors have been identified by epidemiologists. The impact of most of these factors has yet to be fully understood at the organism, tissue, cellular and molecular levels. Importantly, combinations of external and internal risk and protective factors involve cooperativity thus, synergizing or antagonizing disease onset. Models are needed to mechanistically decipher cancer risks under defined cellular and microenvironmental conditions. Here, we briefly review breast cancer risk models based on 3D cell culture and propose to improve risk modeling with lab-on-a-chip approaches. We suggest epithelial tissue polarity, DNA repair and epigenetic profiles as endpoints in risk assessment models and discuss the development of 'risks-on-chips' integrating biosensors of these endpoints and of general tissue homeostasis. Risks-on-chips will help identify biomarkers of risk, serve as screening platforms for cancer preventive agents, and provide a better understanding of risk mechanisms, hence resulting in novel developments in disease prevention.

Indexed as

Biomarkers, TumorBreast NeoplasmsCell Culture TechniquesDNA RepairFemaleHumansRisk AssessmentBiomarkers, Tumor

Identifiers

PMID23681255
PMCPMC3748262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.